PROTEIN A RESIN MARKET ANALYSIS

The high costs associated with Protein A resins is one of the major factors restraining the growth of the global Protein A resin market. Protein A resins are expensive chromatography media used routinely in the downstream purification processes of monoclonal antibody manufacturing. The cost of resins contributes significantly to the overall production costs for biopharmaceutical companies. Protein A resin needs to be replaced on a regular basis as it has durability limitations. It can be effectively used only for a certain number of purification cycles before the binding capacity reduces significantly. Companies need to purchase fresh resins frequently to sustain production. This repetitive capital expenditure on resins every year burdens the budget of companies. The high resin replacement cost discourages wider adoption of Protein A chromatography techniques, especially in developing economies. It also disincentivizes research initiatives involving large-scale screening of monoclonal antibodies.

Market Opportunities: Emerging markets in Asia Pacific and Latin America

The emerging markets in Asia Pacific and Latin America present a huge growth opportunity for the Global Protein A Resin Market. These regions are witnessing rapid economic development and rise in disposable income levels, which is driving increased healthcare spending. At the same time, the prevalence of chronic diseases is also on the rise in countries such as China, India, Brazil, and Mexico due to aging population and changing lifestyles. This is generating high demand for biologics and monoclonal antibody-based drugs which are used for the treatment of cancer, autoimmune disorders, and other complex diseases. Protein A resin is a critical component used in the downstream purification process of monoclonal antibody production. With the biologics industry shifting focus towards these emerging regions to cater to the growing in-house demand, there will be a parallel rise in need for protein A resins. Both multinational pharma companies as well as the domestic players in these markets are expanding and establishing new manufacturing facilities for biologics. For instance, recent data from the International Trade Administration shows that FDI inflows for the biopharma sector increased by 35% in China and 12% in Brazil during 2020-2021 compared to the previous two years. This points towards the prioritization of biologics production in these countries.